Colorectal Cancer
Conditions
Keywords
adenocarcinoma of the rectum, recurrent rectal cancer, stage II rectal cancer, stage III rectal cancer, stage IV rectal cancer
Brief summary
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors understand how patients respond to treatment. PURPOSE: This clinical trial is studying biomarkers in patients with rectal cancer undergoing chemotherapy and radiation therapy.
Detailed description
OBJECTIVES: Primary * Observe whether NF-kappa B is activated in response to treatment with external beam radiotherapy. * Correlate NF-kappa B pathway activation (presumed to be anti-apoptotic in nature) with therapeutic outcomes (as measured by rate of pathologic complete response or downstaging by endoscopic ultrasound \[EUS\]). Secondary * Study downstream events induced by NF-kappa B activation. * Determine global gene expression profiles at baseline and during chemoradiotherapy. * Correlate changes in gene expression (compared with the baseline gene expression pattern) induced by a single dose of external beam radiotherapy with patient outcomes (as measured by pathologic response rate or downstaging by EUS). * Study downstream events related to activation of p53 in response to treatment with radiotherapy. * Correlate p53 pathway-mediated events with clinical outcomes. OUTLINE: Patients receive fluorouracil or capecitabine and undergo radiotherapy and surgery per standard care. Patients undergo tumor pinch biopsies at baseline and on days 1 and 2 of chemoradiotherapy. At the time of final surgical resection, a portion of the remaining rectal tumor will be liquid nitrogen banked. Patients not deemed surgical candidates are evaluated by transrectal ultrasound 6-8 weeks after completion of chemoradiotherapy to assess ultrasound response (downstaging versus no downstaging). Tumor tissue samples are analyzed for NF-kappa B pathway activation; downstream events induced by NF-kappa B activation; changes in global gene expression; p53 function; apoptosis; and mRNA expression. Laboratory techniques used include tissue microarray, ELISA, RNase protection assay, fluorescence semi-quantitative PCR, TUNEL, IHC, and cDNA microarray analysis. If normal tissue from biopsies is not available, whole blood may be collected at any point while patient remains on study for correlative analysis or research related to rectal cancer.
Interventions
DRUGcapecitabine
Capecitabine administration (where deemed appropriate by the treating medical oncologist) will commence on the second day of radiotherapy after the 24-hour biopsy has been performed. Dosing will be per current standard of care at the discretion of the treating Medical, Radiation and Surgical Oncologist
DRUG5-fluorouracil
Administration of 5-fluorouracil (where deemed appropriate by the treating medical oncologist) will commence on the second day of radiotherapy after the 24-hour biopsy has been performed. Dosing and dose modification will be per current standard of care at the discretion of the treating Medical, Radiation and Surgical Oncologist.
PROCEDURESurgical Resection
Surgery will occur approximately 2-6 weeks after chemoradiation depending on clinical factors (i.e. resectability, presence or absence of metastatic disease).
RADIATIONRadiation therapy
Dosing and dose modification will be per current standard of care at the discretion of the treating Radiation Oncologist.
Sponsors
National Cancer Institute (NCI)
UNC Lineberger Comprehensive Cancer Center
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
DISEASE CHARACTERISTICS: * Must have rectal or sigmoid-rectal junction adenocarcinoma confirmed by sigmoidoscopy and pathologic diagnosis of biopsy sample * Inferior margin of the tumor less than 15 cm from anal verge by rigid sigmoidoscopy or below the level of S1-2 at surgery * Candidate for chemotherapy and radiotherapy, as defined by any of the following: * Tumor staged as T3 or N1-2 by rectal sonography * Tumor occupying \> 40% of circumference of rectum * Tumor fixed to extra colonic structures as determined by digital rectal examination * Tumor \< 5 cm from sphincter mechanism * Patient has inoperable disease and is being treated for palliation * Pelvic or anastomotic recurrences of previously resected rectal cancer * Planning to undergo chemotherapy and radiotherapy * No sigmoid carcinoma (carcinoma proximal to the pelvic peritoneal reflection) PATIENT CHARACTERISTICS: * Not pregnant PRIOR CONCURRENT THERAPY: * See Disease Characteristics
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Activation of NF-kappa B in response to treatment with external beam radiotherapy | 6-8 weeks after chemoradiation |
| Correlation of NF-kappa B pathway activation with therapeutic outcomes | 6-8 weeks after chemoradiation |
Secondary
| Measure | Time frame |
|---|---|
| Correlation of changes in gene expression with patient outcomes | 72 days post chemoradiation |
| Downstream events induced by NF-kappa B activation | 12 months |
| Correlation of p53 pathway-mediated events with clinical outcomes | 72 days post chemoradiation |
| Downstream events related to activation of p53 in response to treatment with radiotherapy | 72 post radiotherapy |
| Global gene expression profiles at baseline and during chemoradiotherapy | prior to chemoradiation and 72 days post chemoradiation |
Countries
United States
Outcome results
None listed